Adherence to medication

New England Journal of Medicine

Volumn 353, Issue 5, 2005, Pages 487-497

  Osterberg, Lars ^a   Blaschke, Terrence ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT;

BEHAVIOR MODIFICATION; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; DEPRESSION; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG MONITORING; EDUCATION PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; OBSERVATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT MONITORING; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SELF REPORT; ADOLESCENT; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION; DRUG THERAPY; MENTAL DISEASE; PSYCHOLOGICAL ASPECT; STATISTICS;

ADOLESCENT; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; HIV INFECTIONS; HUMANS; HYPERTENSION; MENTAL DISORDERS; PATIENT COMPLIANCE;

EID: 23044442340     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra050100     Document Type: Review

References (127)

1. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med 2000;132:926-30.
2. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
3. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73.
4. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-3.
5. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
6. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999;17:1041-5.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
8. Rudd P, Byyny RL, Zachary V, et al. Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1988;1:309-12.
9. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-8.
10. Spilker B. Methods of assessing and improving compliance in clinical trials. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:37-56.
11. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000;5:Suppl 1:S31-S34.
12. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;2:CD000011.
13. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1-11.
14. Murri R, Ammassari A, Trotta MP, et al. Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004;19:1104-10.
15. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6.
16. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114:625-30.
17. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126-32.
18. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002;28:266-72. (In French.)
19. Rodgers PT, Ruffin DM. Medication nonadherence: Part II - a pilot study in patients with congestive heart failure. Manag Care Interface 1998;11(9):67-9, 75.
20. Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for drug labeling. Clin Pharmacol Ther 2000;68:586-91.
21. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27:Suppl 9:S1-S24.
22. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-41.
23. LaRosa JC. Poor compliance: the hidden risk factor. Curr Atheroscler Rep 2000;2:1-4.
24. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993;153:1863-8.
25. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-91.
26. Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 1998;12:2305-11.
27. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003. (Accessed July 11, 2005, at http://www.who.int/chronic_ conditions/en/adherence_report.pdf.)
28. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-77.
29. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980;2:757-64.
30. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 2001;54:Suppl 1:S91-S98.
31. Alcoba M, Cuevas MJ, Perez-Simon MR, et al. Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. J Acquir Immune Defic Syndr 2003;33:253-8.
32. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7. [Erratum, JAMA 1989;262:1472.]
33. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16.
34. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-25.
35. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164-70.
36. Spector SL, Kinsman R, Mawhinney H, et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. J Allergy Clin Immunol 1986;77:65-70.
37. Norell SE. Monitoring compliance with pilocarpine therapy. Am J Ophthalmol 1981;92:727-31.
38. Kass MA, Meltzer DW, Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol 1984;102:1550-4.
39. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002;31:Suppl 3:S103-S106.
40. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997;32:345-56.
41. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77. [Erratum, Ann Intern Med 2002;136:175.]
42. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med 2001;134:1004-6.
43. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-7.
44. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:1377-8.
45. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
46. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 2002;54:212-20.
47. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
48. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
49. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65.
50. DiMatteo MR, Sherbourne CD, Hays RD, et al. Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol 1993;12:93-102.
51. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virusinfected men and women. AIDS Patient Care STDS 2002;16:269-81.
52. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002;31:Suppl 3:S123-S127.
53. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-24.
54. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 2001;57:589-94.
55. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44.
56. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
57. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.
58. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 2003;33:211-8.
59. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20:764-71.
60. Ellis JJ, Erickson SR, Stevenson JG. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.
61. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, selfreported adherence, and HIV patients' understanding of their regimens: survey of women in the HER Study. J Acquir Immune Defic Syndr 2001;28:124-31.
62. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination: is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
63. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care 1986;24:67-74.
64. Cramer J. Identifying and improving compliance patterns. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:387-92.
65. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes: overcoming barriers to effective control. Postgrad Med 2000;107:29-32, 35-6, 38.
66. Black HR. Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited. Am J Hypertens 1999;12:225S-230S.
67. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 2002;14:309-18.
68. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003;157:249-55.
69. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood) 1999;18(2):201-12.
70. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care 2005;11(Special Issue):SP27-SP34.
71. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000;2:510-4.
72. Patton K, Meyers J, Lewis BE. Enhancement of compliance among patients with hypertension. Am J Manag Care 1997;3:1693-8.
73. Ran MS, Xiang MZ, Chan CL, et al. Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia - a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 2003;38:69-75.
74. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003;9:404-11.
75. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 2003;11:185-98.
76. Maro EE, Lwakatare J. Medication compliance among Tanzanian hypertensives. East Afr Med J 1997;74:539-42.
77. Ross FM. Patient compliance - whose responsibility? Soc Sci Med 1991;32:89-94.
78. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:I16-I18.
79. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000;15:841-7.
80. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-64.
81. Cramer JA. Optimizing long-term patient compliance. Neurology 1995;45:Suppl 1:S25-S28.
82. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care 1997;8(4):43-54.
83. Osterberg LG, Rudd P. Medication adherence for antihypertensive therapy. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector's The Kidney. 2nd ed. Philadelphia: Elsevier Mosby, 2005:848.
84. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002;7:185-93.
85. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17:169-77.
86. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
87. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther 2001;39:1151-62.
88. Golin CE, DiMatteo MR, Gelberg L. The role of patient participation in the doctor visit: implications for adherence to diabetes care. Diabetes Care 1996;19:1153-64.
89. Shon KH, Park SS. Medication and symptom management education program for the rehabilitation of psychiatric patients in Korea: the effects of promoting schedule on self-efficacy theory. Yonsei Med J 2002;43:579-89.
90. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials 1997;18:187-203.
91. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004;164:722-32.
92. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19:335-41.
93. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment nonadherence in psychosis: meta-analysis. Br J Psychiatry 2003;183:197-206.
94. Vergouwen AC, van Hout HP, Bakker A. Methods to improve patient compliance in the use of antidepressants. Ned Tijdschr Geneeskd 2002;146:204-7. (In Dutch.)
95. Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-55.
96. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
97. Mundt JC, Clarke GN, Burroughs D, Brenneman DO, Griest JH. Effectiveness of antidepressant pharmacotherapy: the impact of medication compliance and patient education. Depress Anxiety 2001;13:1-10.
98. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002;2:CD002831.
99. Molassiotis A, Lopez-Nahas V, Chung WY, Lam SW. A pilot study of the effects of a behavioural intervention on treatment adherence in HIV-infected patients. AIDS Care 2003;15:125-35.
100. Fulmer TT, Feldman PH, Kim TS, et al. An intervention study to enhance medication compliance in community-dwelling el-derly individuals. J Gerontol Nurs 1999;25:6-14.
101. Dunbar PJ, Madigan D, Grohskopf LA, et al. A two-way messaging system to enhance antiretroviral adherence. J Am Med Inform Assoc 2003;10:11-5.
102. Mitchell PB, Mitchell MS. The management of depression. Part 2: the place of the new antidepressants. Aust Fam Physician 1994;23:1771-3, 1776-81.
103. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry 2003;64:Suppl 18:25-30.
104. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-6.
105. Hoffman L, Enders J, Luo J, Segal R, Pippins J, Kimberlin C. Impact of an antidepressant management program on medication adherence. Am J Manag Care 2003;9:70-80.
106. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59:Suppl 8:S10-S15.
107. Gillis LS, Trollip D, Jakoet A, Holden T. Non-compliance with psychotropic medication. S Afr Med J 1987;72:602-6.
108. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87-92.
109. Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer 1986;58:1179-84.
110. Friedman IM, Litt IF. Adolescents' compliance with therapeutic regimens: psychological and social aspects and intervention. J Adolesc Health Care 1987;8:52-67.
111. Friedman IM, Litt IF, King DR, et al. Compliance with anticonvulsant therapy by epileptic youth: relationships to psychosocial aspects of adolescent development. J Adolesc Health Care 1986;7:12-7.
112. Michaud PA, Suris JC, Viner R. The adolescent with a chronic condition. Part II: healthcare provision. Arch Dis Child 2004;89:943-9.
113. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993;71:Suppl 10:3441-9.
114. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003;9:155-71.
115. Brackis-Cott E, Mellins CA, Abrams E, Reval T, Dolezal C. Pediatric HIV medication adherence: the views of medical providers from two primary care programs. J Pediatr Health Care 2003;17:252-60.
116. Jay S, Litt IF, Durant RH. Compliance with therapeutic regimens. J Adolesc Health Care 1984;5:124-36.
117. Rapoff MA. Compliance with treatment regimens for pediatric rheumatic diseases. Arthritis Care Res 1989;2:S40-S47.
118. Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr 1992;120:807-11.
119. Rapoff MA, Lindsley CB, Christophersen ER. Improving compliance with medical regimens: case study with juvenile rheumatoid arthritis. Arch Phys Med Rehabil 1984;65:267-9.
120. Greenan-Fowler E, Powell C, Varni JW. Behavioral treatment of adherence to therapeutic exercise by children with hemophilia. Arch Phys Med Rehabil 1987;68:846-9.
121. Epstein LH, Beck S, Figueroa J, et al. The effects of targeting improvements in urine glucose on metabolic control in children with insulin dependent diabetes. J Appl Behav Anal 1981;14:365-75.
122. Magrab PR, Papadopoulou ZL. The effect of a token economy on dietary compliance for children on hemodialysis. J Appl Behav Anal 1977;10:573-8.
123. Tucker CM, Fennell RS, Pedersen T, Higley BP, Wallack CE, Peterson S. Associations with medication adherence among ethnically different pediatric patients with renal transplants. Pediatr Nephrol 2002;17:251-6.
124. Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004;26:1876-89.
125. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness - which ones work? Metaanalysis of published reports. BMJ 2002;325:925-8.
126. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004;117:182-92.
127. Farris KB, Cote I, Feeny D, et al. Enhancing primary care for complex patients: demonstration project using multidisciplinary teams. Can Fam Physician 2004;50:998-1003.